immunoglobulin [G1-VH-Ckappa_Vkappa-CH1]_[G1_kappa] with domain crossover, anti-[Homo sapiens APP (amyloid beta, A4 precursor protein) Abeta, conformational epitope 1-40/42)] and anti- [Homo sapiens TFRC (transferrin receptor, p90, CD71)], humanized monoclonal antibody, bispecific; fused chain G1-VH-Ckappa bispecific, anti-APP A beta and anti-TFRC (1-702) [gamma1 heavy chain anti-APP Abeta (1-455) humanized [VH (Homo sapiens IGHV3-23*04 (92.9%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.19] (26-33.51-58.97-115)) (1-126) -Homo sapiens IGHG1*01, G1m17,1, G1v32 CH3 W22 (CH1 K26>E (156), K119>E (222), K120 (223) (127-224), hinge 1-15 (225-239), CH2 (240-349), CH3 S10>C (363), D12 (365), L14 (367), T22>W (375) (350-454), CHS K2>del (455)) (127-455)] -18-mer diglycyl-seryl-tris(tetraglycyl-seryl) linker (456-473) -VH-Ckappa chain anti-TFRC (474-702) humanized [VH (Homo sapiens IGHV4-31*02 (76.0%) -(IGHD) -IGHJ5*02 (100%), CDR-IMGT [8.7.19] (498-505.523-529.566-584)) (474-595) -alanylseryl (596-597) -C-KAPPA (Homo sapiens IGKC*01 (100%), Km3 A45.1 (641), V101 (679) (598-702)], (229-215''')-disulfide with kappa light chain anti-APP Abeta (1'''-215''') humanized [V-KAPPA (Homo sapiens IGKV3D-7*01 (89.6%) - IGKJ1*01 (100%), CDR-IMGT [7.3.9] (27-33.51-53.90-98)) (1'''-108''') - Homo sapiens IGKC*01 (100%), Km3 A45.1 (154), V101 (192), E12>R (124), Q13>K (125) (109'''-215''')], (702-215'''')-disulfide with Vkappa- CH1 chain anti-TFRC (1''''-215'''') humanized [V-KAPPA (Homo sapiens IGKV1-13*02 (94.4%) -IGKJ4*01 (100%), CDR-IMGT [6.3.12] (27- 32.50-52.89-100)) (1''''-110'''') -diseryl (111''''-112'''') -CH1-hinge (Homo sapiens IGHG1*01 CH1-h, G1m17 (CH1 K120 (209) (113''''-210''''), hinge 1-5 (211''''-215'''')) (113''''-215'''')], gamma1 heavy chain anti-APP Abeta (1''-456'') humanized [VH (Homo sapiens IGHV3-23*04 (92.9%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.19] (26-33.51-58.97-115)) (1''-126'') -Homo sapiens IGHG1*01, G1m17,1, G1v33 CH3 S22, A24, V86 (CH1 K26>E (156), K119>E (222), K120 (223) (127''-224''), hinge 1-15 (225''-239''), CH2 (240''- 349''), CH3 Y5>C (358), D12 (365), L14 (367), T22>S (375), L24>A (377), Y86>V (416) (350''-454''), CHS (455''-456'')) (127''-456'')], (229''- 215''')-disulfide with kappa light chain anti-APP Abeta (1'''-215''') humanized [V-KAPPA (Homo sapiens IGKV3D-7*01 (89.6%) - IGKJ1*01 (100%), CDR-IMGT [7.3.9] (27-33.51-53.90-98)) (1'''-108''') - Homo sapiens IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'''- 215''')], dimer (235-235'':238-238'':363-358'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
Alzheimers Disease
